Kathryn H. Ching

Research Investigator at Ligand Pharmaceuticals Incorporated

Dr. Ching received her Ph.D. in Biochemistry and Molecular Biology from Georgetown University Medical Center where she studied the role of small G proteins and their effectors in the immunological response. She completed a post doctoral fellowship at the National Institute of Dental and Craniofacial Development in Bethesda, Maryland. At NIH she developed immunoassays to diagnose and monitor autoimmune and infectious disease. Dr. Ching joined Crystal Bioscience (now Ligand Pharmaceuticals Incorporated) in 2013. She is involved in the development, evaluation and study of Ligand's OmniChicken, a transgenic bird expressing fully human V genes at its heavy and light chain loci.

Kathryn_Ching_Ligand_Pharmaceutical_BioTech_Pharma_Summit

Title: Heavy Chain Only Antibodies to SARS-CoV-2